Literature DB >> 23625632

Role of PTEN in basal cell derived lung carcinogenesis.

Stephen P Malkoski1, Timothy G Cleaver, Joshua J Thompson, Whitney P Sutton, Sarah M Haeger, Karen J Rodriguez, Shi-Long Lu, Daniel Merrick, Xiao-Jing Wang.   

Abstract

Lung adenocarcinoma (AdC) and lung squamous cell carcinoma (SCC) are the most common non-small cell lung cancer (NSCLC) subtypes, however, most genetic mouse models of lung cancer produce predominantly, if not exclusively, AdC. Whether this is secondary to targeting mutations to the distal airway cells or to the use of activating Kras mutations that drive AdC formation is unknown. We previously showed that targeting Kras(G12D) activation and transforming growth factor β receptor type II (TGFβRII) deletion to airway basal cells via a keratin promoter induced formation of both lung AdC and SCC. In this study we assessed if targeting phosphatase and tensin homologue (PTEN) deletion to airway basal cells could initiate lung tumor formation or increase lung SCC formation. We found that PTEN deletion is capable of initiating both lung AdC and SCC formation when targeted to basal cells and although PTEN deletion is a weaker tumor initiator than Kras(G12D) with low tumor multiplicity and long latency, tumors initiated by PTEN deletion were larger and displayed more malignant conversion than Kras(G12D) initiated tumors. That PTEN deletion did not increase lung SCC formation compared to Kras(G12D) activation, suggests that the initiating genetic event does not dictate tumor histology when genetic alterations are targeted to a specific cell. These studies also confirm that basal cells of the conducting airway are capable of giving rise to multiple NSCLC tumor types.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  Kras; adenocarcinoma; non-small cell lung cancer; squamous cell carcinoma

Mesh:

Substances:

Year:  2013        PMID: 23625632      PMCID: PMC3906215          DOI: 10.1002/mc.22030

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  37 in total

1.  Identification of bronchioalveolar stem cells in normal lung and lung cancer.

Authors:  Carla F Bender Kim; Erica L Jackson; Amber E Woolfenden; Sharon Lawrence; Imran Babar; Sinae Vogel; Denise Crowley; Roderick T Bronson; Tyler Jacks
Journal:  Cell       Date:  2005-06-17       Impact factor: 41.582

2.  Patterns of keratin expression in the murine thymus.

Authors:  A G Farr; S C Braddy
Journal:  Anat Rec       Date:  1989-07

Review 3.  Mouse models for human lung cancer.

Authors:  Ralph Meuwissen; Anton Berns
Journal:  Genes Dev       Date:  2005-03-15       Impact factor: 11.361

4.  The differential effects of mutant p53 alleles on advanced murine lung cancer.

Authors:  Erica L Jackson; Kenneth P Olive; David A Tuveson; Roderick Bronson; Denise Crowley; Michael Brown; Tyler Jacks
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

5.  Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis.

Authors:  Elizabeth Forrester; Anna Chytil; Brian Bierie; Mary Aakre; Agnieszka E Gorska; Ali-Reza Sharif-Afshar; William J Muller; Harold L Moses
Journal:  Cancer Res       Date:  2005-03-15       Impact factor: 12.701

6.  Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice.

Authors:  Xiaoling Xu; Shogo Kobayashi; Wenhui Qiao; Cuiling Li; Cuiying Xiao; Svetlana Radaeva; Bangyan Stiles; Rui-Hong Wang; Nobuya Ohara; Tadashi Yoshino; Derek LeRoith; Michael S Torbenson; Gregory J Gores; Hong Wu; Bin Gao; Chu-Xia Deng
Journal:  J Clin Invest       Date:  2006-06-08       Impact factor: 14.808

7.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.

Authors:  Zhenbang Chen; Lloyd C Trotman; David Shaffer; Hui-Kuan Lin; Zohar A Dotan; Masaru Niki; Jason A Koutcher; Howard I Scher; Thomas Ludwig; William Gerald; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  Nature       Date:  2005-08-04       Impact factor: 49.962

Review 8.  Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium.

Authors:  Alexander Yu Nikitin; Ana Alcaraz; Miriam R Anver; Roderick T Bronson; Robert D Cardiff; Darlene Dixon; Armando E Fraire; Edward W Gabrielson; William T Gunning; Diana C Haines; Matthew H Kaufman; R Ilona Linnoila; Robert R Maronpot; Alan S Rabson; Robert L Reddick; Sabine Rehm; Nora Rozengurt; Hildegard M Schuller; Elena N Shmidt; William D Travis; Jerrold M Ward; Tyler Jacks
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

9.  Inducible activation of oncogenic K-ras results in tumor formation in the oral cavity.

Authors:  Carlos Caulin; Thao Nguyen; Mary A Longley; Zhijian Zhou; Xiao-Jing Wang; Dennis R Roop
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

Review 10.  Lung cancer and lung stem cells: strange bedfellows?

Authors:  Adam Giangreco; Karen R Groot; Sam M Janes
Journal:  Am J Respir Crit Care Med       Date:  2006-12-07       Impact factor: 21.405

View more
  8 in total

1.  Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression.

Authors:  Chunxiao Xu; Christine M Fillmore; Shohei Koyama; Hongbo Wu; Yanqiu Zhao; Zhao Chen; Grit S Herter-Sprie; Esra A Akbay; Jeremy H Tchaicha; Abigail Altabef; Jacob B Reibel; Zandra Walton; Hongbin Ji; Hideo Watanabe; Pasi A Jänne; Diego H Castrillon; Anil K Rustgi; Adam J Bass; Gordon J Freeman; Robert F Padera; Glenn Dranoff; Peter S Hammerman; Carla F Kim; Kwok-Kin Wong
Journal:  Cancer Cell       Date:  2014-05-01       Impact factor: 31.743

2.  Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.

Authors:  Youngtae Jeong; Ngoc T Hoang; Alexander Lovejoy; Henning Stehr; Aaron M Newman; Andrew J Gentles; William Kong; Diana Truong; Shanique Martin; Aadel Chaudhuri; Diane Heiser; Li Zhou; Carmen Say; Justin N Carter; Susan M Hiniker; Billy W Loo; Robert B West; Philip Beachy; Ash A Alizadeh; Maximilian Diehn
Journal:  Cancer Discov       Date:  2016-09-23       Impact factor: 39.397

Review 3.  Non-small-cell lung cancers: a heterogeneous set of diseases.

Authors:  Zhao Chen; Christine M Fillmore; Peter S Hammerman; Carla F Kim; Kwok-Kin Wong
Journal:  Nat Rev Cancer       Date:  2014-08       Impact factor: 60.716

4.  Smad4 loss promotes lung cancer formation but increases sensitivity to DNA topoisomerase inhibitors.

Authors:  Sarah M Haeger; Joshua J Thompson; Sean Kalra; Timothy G Cleaver; Daniel Merrick; Xiao-Jing Wang; Stephen P Malkoski
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

5.  SOX2 Is the Determining Oncogenic Switch in Promoting Lung Squamous Cell Carcinoma from Different Cells of Origin.

Authors:  Giustina Ferone; Ji-Ying Song; Kate D Sutherland; Rajith Bhaskaran; Kim Monkhorst; Jan-Paul Lambooij; Natalie Proost; Gaetano Gargiulo; Anton Berns
Journal:  Cancer Cell       Date:  2016-10-10       Impact factor: 31.743

6.  Prevalence of NRAS, PTEN and AKT1 gene mutations in the central nervous system metastases of non-small cell lung cancer.

Authors:  Marcin Nicoś; Paweł Krawczyk; Bożena Jarosz; Marek Sawicki; Tomasz Trojanowski; Janusz Milanowski
Journal:  Brain Tumor Pathol       Date:  2017-01-17       Impact factor: 3.298

7.  Development of syngeneic murine cell lines for use in immunocompetent orthotopic lung cancer models.

Authors:  Kyle Nolan; Gregory Verzosa; Tim Cleaver; Darinee Tippimanchai; Lisa N DePledge; Xiao-Jing Wang; Christian Young; Anh Le; Robert Doebele; Howard Li; Stephen P Malkoski
Journal:  Cancer Cell Int       Date:  2020-08-28       Impact factor: 5.722

8.  Histologic transformation of lung adenocarcinoma to squamous cell carcinoma after chemotherapy: two case reports.

Authors:  Yi Shao; Dian-Sheng Zhong; Sha-Sha Guan
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.